Ind-Swift possesses state-of-the-art manufacturing facilities for finished Dosage Forms & API's conforming to the most stringent international norms of WHO-GMP, TGA (Australia), MHRA (UK).
Ind-Swift has a manufacturing capacity of (Finished Dosage) :
  •  2300 million Tablets
  •  64 million Ampoules
  •  27 million Vials
  •  84 million Capsules
  •  18 million Dermatological products
  •  62 million Oral liquid bottles
Manufacturing capacity (API) :
  •  1,50,0000 (15 lakhs) sq. ft. covered area
  •  11 Dedicated blocks operating as per USFDA guidelines.
  •  700 Stainless Steel and Glass Lined Reaction Vessels with capacities ranging from 50 to 6000 liters. (Total Volume 1000 kilo liters).
  •  3 Automated Fluidized bed coaters with capacity of manufacturing 4 Metric tonn of Granules per month.
  •  CGMP pilot plant having 10 reaction vessels with capacities ranging from 250 to 1000 liters( Total volume 5.5 kilo-liters)
  •  Fully Automated Solvent Recovery System
  •  Biological waste water treatment plant.
  •  Approvals from TGA (Australia), USFDA, WHO-GMP, MHRA(UK),NDA (Uganda),TFDA(Tanzania),UAEC, DACA-(Ethiopia),GMP(Yemen).
Ind-Swift has an R & D facility duly approved by the Department Of Science of Technology and the Govt of India. This facility has eight synthetic labs with over 40,000 Sq ft of research area and the best pool of scientists and researchers.